Record Display for the EPA National Library Catalog


OLS Field Name OLS Field Data
Main Title Initial Submission: Letter from FMC Corp. to USEPA re: Preliminary, Unaudited Results from 1-Generation Reproduction Study in Rats of Hydroxyphospnonoacetic Acid, dated 11/22/1995.
CORP Author FMC Corp., Philadelphia, PA.; Environmental Protection Agency, Washington, DC. Office of Toxic Substances.
Year Published 1995
Report Number 8EHQ-1195-13549
Stock Number OTS0558423
Additional Subjects Toxicology ; Health effects ; Toxic substances ; Hydroxyphosphonoacetic acid ; Laboratory animals ; Subchronic toxicity ; Mammals ; Rats ; Oral ; Gavage ; Reproduction/fertility effects ; Combined teratogenicity/reproductive effects ; CAS No 23783-26-8
Library Call Number Additional Info Location Last
NTIS  OTS0558423 Most EPA libraries have a fiche copy filed under the call number shown. Check with individual libraries about paper copy. NTIS 05/12/2010
Collation 9p
On November 22, 1995, FMC Corporation informed the Agency of adverse effects observed during a 1-Generation Reproduction Study conducted in rats with Hydroxyphosphonoacetic acid, CAS Registry Number 23783-26-8. The specific reportable effect was the high level of mortality of females post parturition. Continuing with this same study, FMC now wishes to notify the Agency of a further adverse finding: Hydroxyphosphonoacetic acid (HPA) was evaluated for potential reproductive toxicity in a one generation study. Groups of Sprague-Dawley rats were dosed orally by gavage for ten weeks prior to mating and throughout mating, gestation and lactation periods. Dose levels were 0, 1, 10, 50, 150 and 500 mg/kg/day. The test material is a phosphonate and is expected to deplete calcium levels. Because the females were pregnant and had a higher calcium requirement for the developing fetuses and for the nursing pups, depletion of calicum stores may have contributed to the toxicity of the parents and the decreased viabiliity/survival of the pups. During late gestation there were maternal deaths at the top two dose levels, reported previously in a TSCA 8(e) report.